Samsung Biologics surpassed ₩2 trillion in sales

in 3 quarters

Rapid growth of bio-CDMO

Samsung BioLogics surpassed 2 trillion won in cumulative sales in the third quarter.

 

It exceeded 1.568 trillion won in annual sales last year in three quarters.

 

On the 26th, Samsung BioLogics announced that it achieved 873 billion won in sales and 324.7 billion won in operating profit in the third quarter.

 

Both sales and operating profit rose 94% year-on-year.

 

Cumulative sales are 2.358 trillion won on a consolidated basis.

 

It is the first time since its foundation that Samsung BioLogics has surpassed 2 trillion won in sales.

 

◆ Samsung BioLogics exceeded sales last year in three quarters Samsung BioLogics explained that it recorded cumulative sales of 1.6896 trillion won and an operating profit of 659.5 billion won in the third quarter, exceeding its annual performance last year (sales of 1.568 trillion won and operating profit of 536.5 billion won).

 

Samsung BioLogics incorporated Samsung Bioepis as a 100% subsidiary in April this year.

 

Samsung BioLogics explained that this results from increased sales of raw material drug CMO (consignment production) and increased profits of CDO (consignment development).

 

On top of that, it added that the rise in the exchange rate led to improved performance.

 

Samsung BioLogics plans to strengthen its business by operating its fourth plant in earnest and expanding orders for CDMO.

 

Samsung BioLogics' fourth plant has the world's largest production capacity with a total of 240,000 liters.

 

It started partial operation this month and will be in full operation next year.

 

When the fourth plant is operated next year, Samsung BioLogics' production capacity will be expanded to 604,000 liters.

 

It is the largest in the global CDMO industry.

 

In the CDO business sector, it has expanded its portfolio by launching a new dual antibody platform called 'S-dual'.

 

The cumulative number of orders is 73 for CMO and 100 for CDO.

 

Cumulative charges amount to $8.5 billion (about 12 trillion won).

 

◆ Samsung Bioepis' performance decreases Samsung Bioepis recorded 269.8 billion won in sales and 77.9 billion won in operating profit in the third quarter on a separate basis.

 

Sales fell 0.5% year-on-year and operating profit fell 23%.

 

In the third quarter of last year, it received licensed milestones for U.S.

 

and European products.

 

Although its performance declined due to the base effect, the company explained that sales and operating profit are steadily growing this year as product sales growth in the global market.

 

Samsung Bioepis is selling a total of six biosimilars in the global market.

 

In the third quarter of this year, it obtained U.S.

 

permission for the "Humira" biosimilar (SB5) high-concentration formulation.

 

It plans to complete phase 3 clinical trials of Prolia biosimilar (SB16) and Stella biosimilar (SB17) within this year.